DeepHealth expands AI breast cancer imaging with iCAD acquisition
RadNet's subsidiary DeepHealth has completed its acquisition of iCAD, bringing together two companies in the field of artificial intelligence (AI)-driven breast cancer imaging solutions.
The acquisition brings iCAD's commercial, technological, and regulatory assets under DeepHealth's management. According to RadNet, this move is expected to enhance DeepHealth's capabilities in AI-powered breast cancer image interpretation and workflow systems, broadening its reach and impact in global breast cancer screening and diagnosis.
Portfolio expansion
iCAD's portfolio, which covers breast cancer detection, risk evaluation, breast density assessment, and identification of breast arterial calcification, is currently used in over 50 countries and more than 1,500 healthcare provider locations. DeepHealth intends to incorporate these technologies with its own end-to-end screening and diagnostic platforms, aiming to support both higher detection rates and more efficient medical workflows.
The integration is expected to accelerate the adoption of AI across the breast cancer screening pathway and to expand access to these technologies worldwide. The combined resources mean DeepHealth can process over 10 million mammograms annually, including in regions that often have reduced access to advanced diagnostic tools.
Leadership comments
"We are excited to welcome the iCAD team to DeepHealth. The integration of iCAD further empowers DeepHealth to meet the real-world clinical needs of today, from improving the accuracy and early detection of breast cancer to orchestrating large-scale screening programs, while shaping the future of breast cancer management. Our combined capabilities position us for accelerated growth and rapid delivery of transformative, AI-powered population health solutions."
This statement was made by Kees Wesdorp, President and Chief Executive Officer of RadNet's Digital Health segment, reflecting on the prospective value brought by merging iCAD's solutions and expertise into DeepHealth.
Scale and access
The acquisition provides DeepHealth with significantly increased market access through iCAD's network, aiming to facilitate the rollout of advanced AI-driven screening solutions in both established and underserved healthcare markets. The unified portfolio will allow further development of AI models using a more extensive and diversified data set and clinical infrastructure.
DeepHealth's technology platform is used by thousands of radiologists and imaging centres globally for disease detection, including in large-scale cancer screening programmes. With the addition of iCAD's channels and installed technology, DeepHealth aims to further its mission of enhancing early and reliable disease detection through AI.
Strategic context
RadNet is responsible for a network of 401 outpatient imaging centres in the United States and provides digital health services under the DeepHealth brand. Alongside breast cancer solutions, DeepHealth's portfolio also covers AI-driven imaging for lung, prostate, brain, and thyroid health.
RadNet has stated that the integration of iCAD will enhance its strategic ability to address both operational and clinical challenges by harnessing existing and emerging AI technologies. Use of DeepHealth's cloud-native operating system is intended to connect clinical data across workflows and personalise the working environment for radiology professionals.
Outlook
RadNet has highlighted the anticipated benefits of the acquisition, suggesting it may enable more rapid innovation, stronger clinical outcomes, and broader adoption of AI-driven medical imaging worldwide. DeepHealth's expansion, supported by iCAD's network and technology, is expected to shape developments for population-level breast cancer health management and detection.
Details regarding the integration process, operational adjustments, and any planned product development resulting from the combined capabilities have not been disclosed.
